SG11202010496WA - Anti-muc1 antibody-drug conjugate - Google Patents
Anti-muc1 antibody-drug conjugateInfo
- Publication number
- SG11202010496WA SG11202010496WA SG11202010496WA SG11202010496WA SG11202010496WA SG 11202010496W A SG11202010496W A SG 11202010496WA SG 11202010496W A SG11202010496W A SG 11202010496WA SG 11202010496W A SG11202010496W A SG 11202010496WA SG 11202010496W A SG11202010496W A SG 11202010496WA
- Authority
- SG
- Singapore
- Prior art keywords
- drug conjugate
- muc1 antibody
- muc1
- antibody
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18173253 | 2018-05-18 | ||
PCT/EP2019/062758 WO2019219891A1 (en) | 2018-05-18 | 2019-05-17 | Anti-muc1 antibody-drug conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010496WA true SG11202010496WA (en) | 2020-12-30 |
Family
ID=62217845
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010493XA SG11202010493XA (en) | 2018-05-18 | 2019-05-17 | Anti-muc1 antibody |
SG11202010496WA SG11202010496WA (en) | 2018-05-18 | 2019-05-17 | Anti-muc1 antibody-drug conjugate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010493XA SG11202010493XA (en) | 2018-05-18 | 2019-05-17 | Anti-muc1 antibody |
Country Status (22)
Country | Link |
---|---|
US (4) | US20210187118A1 (de) |
EP (4) | EP3794042B1 (de) |
JP (3) | JP7257422B2 (de) |
KR (2) | KR20210010565A (de) |
CN (3) | CN117815404A (de) |
AU (2) | AU2019270457A1 (de) |
BR (2) | BR112020023346A2 (de) |
CA (2) | CA3100745A1 (de) |
CO (2) | CO2020013664A2 (de) |
DK (1) | DK3794042T3 (de) |
ES (1) | ES2951674T3 (de) |
HR (1) | HRP20230787T1 (de) |
HU (1) | HUE063066T2 (de) |
LT (1) | LT3794042T (de) |
MX (2) | MX2020011997A (de) |
PH (2) | PH12020551969A1 (de) |
PL (1) | PL3794041T3 (de) |
RS (1) | RS64379B1 (de) |
SG (2) | SG11202010493XA (de) |
TW (2) | TW202402806A (de) |
WO (2) | WO2019219889A1 (de) |
ZA (1) | ZA202006684B (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210187118A1 (en) * | 2018-05-18 | 2021-06-24 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
KR20210038625A (ko) * | 2018-07-31 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 |
JP2022541747A (ja) | 2019-07-10 | 2022-09-27 | サイブレクサ 3,インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
AU2020309570A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
MX2023000544A (es) * | 2020-07-13 | 2023-02-13 | Regeneron Pharma | Conjugados de proteina-farmaco que comprenden analogos de camptotecina y metodos de uso de los mismos. |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CN116059339B (zh) * | 2021-11-04 | 2023-09-22 | 元本(珠海横琴)生物科技有限公司 | 一种治疗和预防癌症的药物和应用 |
US20230287138A1 (en) * | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
WO2023201234A2 (en) * | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4931275A (en) | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
JPH06508985A (ja) | 1991-02-27 | 1994-10-13 | クリエイティブ バイオモレキュルズ インコーポレイテッド | 富セリンペプチドリンカー |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
AU683413B2 (en) | 1992-04-13 | 1997-11-13 | Dana-Farber Cancer Institute, Inc. | Antibodies specific for carcinoma-associated antigens |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
DE4329004A1 (de) | 1993-08-28 | 1995-03-09 | Max Delbrueck Centrum | Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis |
AU7965694A (en) | 1993-10-15 | 1995-05-04 | Curators Of The University Of Missouri, The | Dna encoding the human p2u receptor and null cells expressing p2u receptors |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
JPH11509088A (ja) | 1995-06-23 | 1999-08-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 血管内皮増殖因子受容体をコードする遺伝子の転写調節 |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
EP0906444A1 (de) | 1996-04-19 | 1999-04-07 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
JP2001523480A (ja) | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO1999061061A1 (fr) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
EA003790B1 (ru) | 1998-10-30 | 2003-10-30 | Дайити Фармасьютикал Ко., Лтд. | Соединение сдлс и способ его измерения |
US6465220B1 (en) | 1998-12-21 | 2002-10-15 | Glycozym Aps | Glycosylation using GalNac-T4 transferase |
AUPP816899A0 (en) | 1999-01-14 | 1999-02-11 | Food Technology Innovations Pty Limited | Improved microbial products |
AU3508300A (en) | 1999-03-02 | 2000-09-21 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
EP1167537B1 (de) | 1999-03-30 | 2008-07-23 | Japan Tobacco Inc. | Verfahren zur herstellung von monoklonalen antikörpern |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
EP1191944A2 (de) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | Methoden zur behandlung unter verwendung von erb antibody-mayntasinoid konjugate |
US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
WO2001023421A2 (en) | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
EP1268800A2 (de) | 2000-03-30 | 2003-01-02 | Dyax Corporation | Mucin-1-spezifische bindungsmitglieder und verfahren zur deren verwendung |
GB2362531A (en) | 2000-05-15 | 2001-11-21 | Nokia Mobile Phones Ltd | Indicating the temporal order of reference frames in a video sequence |
FR2809312B1 (fr) | 2000-05-25 | 2002-07-12 | Gervais Danone Sa | Utilisation de l. casei dans des compositions immunostimulantes |
WO2002000734A1 (fr) | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
US6815435B2 (en) | 2000-07-13 | 2004-11-09 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing DDS compounds |
FR2814096B1 (fr) | 2000-09-15 | 2002-12-27 | Montupet Sa | Procede de fabrication de pieces de fonderie munies d'inserts avec cohesion mecanique piece/insert amelioree, et insert utilisable dans un tel procede |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
WO2002061118A1 (fr) | 2001-02-01 | 2002-08-08 | Kabushiki Kaisha Yakult Honsha | Methode d'evaluation de l'acces a l'intestin d'une bacterie bifidus contenue dans un aliment ou une boisson a base de lait fermente |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
EP1283053A1 (de) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitore der HER3 Aktivität |
US20050042714A1 (en) | 2001-08-17 | 2005-02-24 | Michael Pawlita | Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
AU2002340562B2 (en) | 2001-10-22 | 2008-10-23 | Merck Serono Sa | Compositions of FSH with high sialylation degree and their use for the preparation of medicaments |
GB0125473D0 (en) | 2001-10-24 | 2001-12-12 | Syngenta Ltd | Chemical process |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
KR100506766B1 (ko) | 2001-11-20 | 2005-08-05 | (주)에이티젠 | 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및이를 포함하는 융합단백질 |
EP1482972A4 (de) | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | Behandlung von immunologischen störungen unter verwendung von anti-cd30 antikörpern |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
KR101002443B1 (ko) | 2002-03-01 | 2010-12-17 | 이뮤노메딕스, 인코오포레이티드 | Rs7 항체 |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
GB0212046D0 (en) | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
DK1529060T3 (en) | 2002-07-22 | 2014-12-15 | Glycotope Gmbh | PROCEDURE FOR PREPARING AN IMMUNSTIMULATORY MUCIN (MUC1) |
ATE482720T1 (de) | 2002-08-16 | 2010-10-15 | Glycotope Gmbh | Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen |
DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
EP1572242B1 (de) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immun-conjugate mit einem intrazellular spaltbaren linker |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1706079B1 (de) | 2003-08-14 | 2013-02-20 | ThromboGenics N.V. | Antikörper gegen faktor viii mit modifizierter glykosilierung in der variablen region |
US8017388B2 (en) | 2003-08-18 | 2011-09-13 | Glycotope Gmbh | Tumour cell lines and uses thereof |
FR2861080B1 (fr) | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
EP1725673A1 (de) | 2004-02-13 | 2006-11-29 | Glycotope Gmbh | Verfahrensbedingungen für sialytierte glykoproteine und effizientes verfahren zu deren produktion |
EP1722797A4 (de) | 2004-02-26 | 2008-03-19 | Inotek Pharmaceuticals Corp | Isochinolin-derivate und anwendungsverfahren dafür |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
SI2301576T1 (sl) * | 2004-03-29 | 2013-02-28 | Abbott Biotherapeutics Corp. | Terapevtska uporaba protiteles proti CS1 |
US20060051353A1 (en) | 2004-05-14 | 2006-03-09 | Jean-Frederic Colombel | Methods and compositions to evaluate antibody treatment response |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
JP4904266B2 (ja) | 2004-07-26 | 2012-03-28 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 抗−tf−抗原抗体の治療的使用 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1817341A2 (de) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Veränderte antikörper und immunkonjugate |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2607663C (en) | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
CA2614046C (en) | 2005-06-30 | 2018-05-15 | Centocor, Inc. | Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof |
GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
JP4919146B2 (ja) * | 2005-09-27 | 2012-04-18 | 独立行政法人産業技術総合研究所 | スイッチング素子 |
US20090181016A1 (en) | 2005-11-30 | 2009-07-16 | University Of Southern California | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US20090046556A1 (en) | 2006-02-14 | 2009-02-19 | Koninklijke Philips Electronics N.V. | Bit detection for optical disc reading |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
WO2007124992A1 (en) | 2006-04-28 | 2007-11-08 | Unilever N.V. | Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
UA95958C2 (en) | 2006-05-30 | 2011-09-26 | Дженентек, Инк. | Antibody that binds to cd22, immunoconjugates and uses therefor |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
EP1900750A1 (de) | 2006-09-18 | 2008-03-19 | Glycotope Gmbh | Vollhumanes System zur Herstellung verbesserter Antikörper mit hoher Ausbeute |
BRPI0716997B8 (pt) | 2006-09-10 | 2021-05-25 | Glycotope Gmbh | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
EP1911766A1 (de) | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Verwendung aus myeloischer Leukämie stammender humaner Zellen für die Exprimierung von Antikörpern |
EP1920781B1 (de) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren |
US20100068181A1 (en) | 2006-12-21 | 2010-03-18 | Schering Corporation | Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
WO2008101177A2 (en) | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
CA2681159A1 (en) | 2007-03-13 | 2008-09-18 | Peros Systems Technologies, Inc. | Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents |
WO2008116219A2 (en) | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
NZ580755A (en) | 2007-04-03 | 2012-05-25 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
KR20210100223A (ko) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
WO2009138220A1 (en) | 2008-05-13 | 2009-11-19 | Glycotope Gmbh | Fermentation process |
EP2277044B1 (de) | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analyse von antikörper-arzneimittel konjugaten mittels perlenbasierter affinitätserfassung und massenspektrometrie |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2741798A1 (en) | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anti-muc1 antibody |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
EP2420515A4 (de) | 2009-04-16 | 2013-08-28 | Univ Tokyo | Diagnose und behandlung von krebs mit anti-tmprss11e-antikörper |
BR112012001395A2 (pt) | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
EP2281844A1 (de) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC-1-Antikörper |
WO2011021397A1 (ja) | 2009-08-20 | 2011-02-24 | 国立大学法人千葉大学 | コルヒチン誘導体 |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
RS56741B1 (sr) | 2009-11-13 | 2018-03-30 | Daiichi Sankyo Europe Gmbh | Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3 |
EP2506881B1 (de) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie |
ES2701626T3 (es) * | 2009-12-28 | 2019-02-25 | Oncotherapy Science Inc | Anticuerpos anti-CDH3 y sus usos |
EP2347769A1 (de) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Krebsstammzellenmarker und Verwendungen damit |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
KR101624381B1 (ko) | 2010-05-17 | 2016-05-25 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 TROP-2 항체 |
MX2012013100A (es) | 2010-05-18 | 2013-01-22 | Cerulean Pharma Inc | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. |
EP2594589A1 (de) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | Anti-trop-2-antikörper |
EP2593142B8 (de) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunktionelle antikörperkonjugate |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
JP6334166B2 (ja) | 2010-08-10 | 2018-05-30 | グリコトープ ゲーエムベーハー | Fabグリコシル化抗体 |
US9051370B2 (en) | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
WO2012064733A2 (en) | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
US9175092B2 (en) | 2011-06-28 | 2015-11-03 | Oxford Biotherapeutics Ltd | Antibodies to bone marrow stromal antigen 1 |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
WO2013087716A2 (de) | 2011-12-14 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US9051365B2 (en) | 2011-12-21 | 2015-06-09 | Novartis Ag | Antibodies that bind factor P |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
AU2013274078A1 (en) | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
BR122021014365B1 (pt) | 2012-10-11 | 2022-07-05 | Daiichi Sankyo Company, Limited | Conjugado de anticorpo-fármaco, fármacos e composição farmacêutica compreendendo os mesmos, e uso |
WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーBioNTech AG | クローディンを発現するガン疾患を処置するための剤 |
JP6262768B2 (ja) | 2013-01-03 | 2018-01-17 | セルトリオン, インク. | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
EP2945964A2 (de) | 2013-01-18 | 2015-11-25 | Glycotope GmbH | Fusionspeptide zur erhöhung der proteinexpression |
KR20160035600A (ko) * | 2013-08-02 | 2016-03-31 | 사노피 | 고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도 |
EP3083686B2 (de) | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindenden antagonisten und taxanen |
PL3088419T3 (pl) | 2013-12-25 | 2019-03-29 | Daiichi Sankyo Company, Limited | Koniugat lek-przeciwciało anty-trop2 |
JP2015138634A (ja) | 2014-01-22 | 2015-07-30 | 株式会社オートネットワーク技術研究所 | 端子金具付き電線及びその製造方法 |
CA2938111C (en) * | 2014-01-29 | 2024-02-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
CA2928794C (en) | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
KR102186027B1 (ko) | 2014-04-10 | 2020-12-03 | 다이이치 산쿄 유럽 게엠베하 | 항her3 항체-약물 콘주게이트 |
GB201406767D0 (en) * | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
KR102262720B1 (ko) | 2014-04-28 | 2021-06-08 | 이카가쿠 소우야쿠 가부시키가이샤 | 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도 |
KR20230028807A (ko) | 2014-06-30 | 2023-03-02 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
LU92659B1 (en) | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
US11485791B2 (en) | 2015-03-17 | 2022-11-01 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
CA3050039A1 (en) | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
EP3601348A1 (de) | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Humanisierte anti-cd40-antikörper |
WO2018178123A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | BISPECIFIC MUC-1 x PD-L1 ANTIBODIES |
EP3601357A1 (de) | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Multispezifische antikörperkonstrukte mit bindung an muc1 und cd3 |
CA3057758A1 (en) | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Pd-l1 and ta-muc1 antibodies |
US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
JP2021514625A (ja) | 2018-03-01 | 2021-06-17 | グリコトープ ゲーエムベーハー | 抗muc1抗体およびil−15を含む融合タンパク質構築物 |
US20210187118A1 (en) | 2018-05-18 | 2021-06-24 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
-
2019
- 2019-05-17 US US17/055,323 patent/US20210187118A1/en active Pending
- 2019-05-17 KR KR1020207036343A patent/KR20210010565A/ko unknown
- 2019-05-17 AU AU2019270457A patent/AU2019270457A1/en active Pending
- 2019-05-17 TW TW112137234A patent/TW202402806A/zh unknown
- 2019-05-17 EP EP19724824.8A patent/EP3794042B1/de active Active
- 2019-05-17 SG SG11202010493XA patent/SG11202010493XA/en unknown
- 2019-05-17 AU AU2019270459A patent/AU2019270459A1/en active Pending
- 2019-05-17 PL PL19724502.0T patent/PL3794041T3/pl unknown
- 2019-05-17 EP EP23174276.8A patent/EP4249002A3/de active Pending
- 2019-05-17 MX MX2020011997A patent/MX2020011997A/es unknown
- 2019-05-17 SG SG11202010496WA patent/SG11202010496WA/en unknown
- 2019-05-17 ES ES19724502T patent/ES2951674T3/es active Active
- 2019-05-17 WO PCT/EP2019/062756 patent/WO2019219889A1/en active Application Filing
- 2019-05-17 BR BR112020023346-3A patent/BR112020023346A2/pt unknown
- 2019-05-17 DK DK19724824.8T patent/DK3794042T3/da active
- 2019-05-17 KR KR1020207036382A patent/KR20210013107A/ko unknown
- 2019-05-17 CN CN202311750783.0A patent/CN117815404A/zh active Pending
- 2019-05-17 EP EP23180419.6A patent/EP4257611A3/de active Pending
- 2019-05-17 BR BR112020023373-0A patent/BR112020023373A2/pt unknown
- 2019-05-17 EP EP19724502.0A patent/EP3794041B1/de active Active
- 2019-05-17 CA CA3100745A patent/CA3100745A1/en active Pending
- 2019-05-17 HU HUE19724502A patent/HUE063066T2/hu unknown
- 2019-05-17 CN CN201980033159.4A patent/CN112351999A/zh active Pending
- 2019-05-17 US US17/055,303 patent/US20210221910A1/en active Pending
- 2019-05-17 RS RS20230586A patent/RS64379B1/sr unknown
- 2019-05-17 CA CA3100608A patent/CA3100608A1/en active Pending
- 2019-05-17 JP JP2020564569A patent/JP7257422B2/ja active Active
- 2019-05-17 WO PCT/EP2019/062758 patent/WO2019219891A1/en active Application Filing
- 2019-05-17 MX MX2020011996A patent/MX2020011996A/es unknown
- 2019-05-17 JP JP2020564656A patent/JP2021524740A/ja active Pending
- 2019-05-17 HR HRP20230787TT patent/HRP20230787T1/hr unknown
- 2019-05-17 TW TW108117151A patent/TWI825098B/zh active
- 2019-05-17 CN CN201980033037.5A patent/CN112449641A/zh active Pending
- 2019-05-17 LT LTEPPCT/EP2019/062758T patent/LT3794042T/lt unknown
-
2020
- 2020-10-27 ZA ZA2020/06684A patent/ZA202006684B/en unknown
- 2020-10-30 CO CONC2020/0013664A patent/CO2020013664A2/es unknown
- 2020-11-18 PH PH12020551969A patent/PH12020551969A1/en unknown
- 2020-11-18 PH PH12020551970A patent/PH12020551970A1/en unknown
- 2020-11-20 CO CONC2020/0014435A patent/CO2020014435A2/es unknown
-
2022
- 2022-08-01 US US17/878,611 patent/US11872289B2/en active Active
- 2022-12-13 JP JP2022198556A patent/JP2023027259A/ja active Pending
-
2023
- 2023-07-10 US US18/349,438 patent/US20230372520A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202010496WA (en) | Anti-muc1 antibody-drug conjugate | |
ZA202001219B (en) | Bcma monoclonal antibody-drug conjugate | |
IL284280A (en) | Conjugate of antibody and oligonucleotide | |
IL273471B1 (en) | Conjugation of an antibody with a pyrrolobenzodiazepine derivative | |
EP3473270A4 (de) | Antikörper-wirkstoff-konjugat | |
IL278990A (en) | Captures of camptothecin | |
SG11202007919RA (en) | Antibody-drug conjugate having acidic self-stabilization junction | |
EP3501548A4 (de) | Auf gewebefaktor gerichtetes antikörper-wirkstoff-konjugat | |
IL269945B (en) | Conjugates of pyrrolobenzodiazepine | |
IL272625A (en) | Conjugates of pyrrolobenzodiazepine | |
SG11202104993SA (en) | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate | |
HK1257352A1 (zh) | 靶向gcc的抗體-藥物綴合物 | |
IL269321A (en) | drug-polymer couple | |
EP3441088A4 (de) | Antikörper-wirkstoff-konjugat mit modifiziertem antikörper | |
GB201820626D0 (en) | Conjugates | |
GB201820864D0 (en) | Antibody-drug conjugates | |
GB201917804D0 (en) | Conjugate | |
IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
GB201906997D0 (en) | Conjugates | |
GB201817110D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201817088D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201900735D0 (en) | Conjugates | |
GB201805086D0 (en) | Enzyme-polymer conjugate |